Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Update

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 123,200 shares, an increase of 27.1% from the October 15th total of 96,900 shares. Based on an average daily trading volume, of 120,900 shares, the short-interest ratio is presently 1.0 days. Approximately 0.7% of the shares of the company are short sold.

Inspira Technologies Oxy B.H.N. Trading Down 2.4 %

IINN opened at $1.22 on Friday. The company has a current ratio of 2.23, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $1.31 and its 200 day moving average price is $1.45. Inspira Technologies Oxy B.H.N. has a fifty-two week low of $0.76 and a fifty-two week high of $2.49.

Institutional Trading of Inspira Technologies Oxy B.H.N.

A hedge fund recently bought a new stake in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC bought a new position in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,497 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.19% of Inspira Technologies Oxy B.H.N. at the end of the most recent reporting period. Institutional investors and hedge funds own 12.72% of the company’s stock.

Inspira Technologies Oxy B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.